ANDA 214319, held by Sun Pharm Inds Inc. Sugammadex Sodium.
As of Nov 16, 2026, ANDA 214319 (Sugammadex Sodium), held by Sun Pharm Inds Inc, was first approved by FDA on Jul 28, 2026, with 0 approved supplements and 0 published complete response letters.
Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. Additional pediatric use information is approved for Merck Sharp & Dohme LLC’s BRIDION (sugammadex) injection. However, due to Merck Sharp & Dohme LLC’s marketing exclusivity rights, this drug product is not labeled with that information.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2026 | Original application | Approved | None posted |
| Sugammadex SodiumEQ 200MG BASE/2ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
| Sugammadex SodiumEQ 500MG BASE/5ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters